Skip to main content
Download PDF

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting

Experimental Hematology & Oncology volume 12, Article number: 86 (2023) Cite this article

The Original Article was published on 26 August 2023

Experimental Hematology & Oncology (2023) 12:74

https://doi.org/10.1186/s40164-023-00436-9

After online publication of the article1, the authors noticed Table 1 and 2 should have been published in the main article were inadvertently submitted and processed as Supplementary files.

The correct tables are published with this erratum.

Table 1 Properties of bispecific antibodies for multiple myeloma
Full size table
Table 2 Outcomes of clinical trials of single-agent bispecific antibodies or combination therapy
Full size table

Author information

Authors and Affiliations

  1. The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, 450008, Zhengzhou, China

    Jiangxue Hou, Yufu Li & Quande Lin

Authors
  1. Jiangxue Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yufu Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Quande Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Quande Lin.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s40164-023-00436-9

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hou, J., Li, Y. & Lin, Q. Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting. Exp Hematol Oncol 12, 86 (2023). https://doi.org/10.1186/s40164-023-00447-6

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s40164-023-00447-6

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us